Michael Offin
Memorial Sloan Kettering Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Michael Offin as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 17:33 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT07532902 · A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor CancerMemorial Sloan Kettering Cancer Center · recruiting · Diffuse Pleural Mesothelioma, Gastroesophageal Carcinoma, Urothelial Carcinoma · principal investigator
- Ph2NCT06477419 · A Study of Sacituzumab Govitecan in People With MesotheliomaMemorial Sloan Kettering Cancer Center · recruiting · Mesothelioma, Mesotheliomas Pleural, Mesothelioma; Pleura · principal investigator
- Ph1NCT05071014 · A Study of Pembrolizumab and Cryoablation in People With MesotheliomaMemorial Sloan Kettering Cancer Center · completed · Lung Cancer, Unresectable Mesothelioma · principal investigator
- Ph1NCT04162015 · A Study of Nivolumab and Chemotherapy Followed by Surgery for MesotheliomaMemorial Sloan Kettering Cancer Center · active not recruiting · Malignant Pleural Mesothelioma · principal investigator
- Ph1NCT04040231 · Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in MesotheliomaMemorial Sloan Kettering Cancer Center · completed · Mesothelioma, Pleural Mesothelioma, Wilms Tumor · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 17:33 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Intraperitoneal CAR T-cell therapy for peritoneal mesotheliomaR01FD008780 · FDA · SLOAN-KETTERING INST CAN RESEARCH · fiscal years 2026 · $650,000 awarded in 2026Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 17:33 UTC. The ranking covers the 200 most relevant of 10 PubMed records, and a shared surname and initials can bring in a namesake. All 10 on PubMed
- Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial.J Clin Oncol · 2018497 citationsRCR 15.3
- MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with MTAP-Deleted Cancer.Cancer Discov · 2023209 citationsRCR 15.8
- Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With BRAFV600-Mutant Metastatic Non-Small-Cell Lung Cancer.J Clin Oncol · 2023123 citationsRCR 9.2
- 65 citationsRCR 13.1
- A Phase I/II Study of Valemetostat (DS-3201b), an EZH1/2 Inhibitor, in Combination with Irinotecan in Patients with Recurrent Small-Cell Lung Cancer.Clin Cancer Res · 202432 citationsRCR 3.5
- Characterization and management of ERK inhibitor associated dermatologic adverse events: analysis from a nonrandomized trial of ulixertinib for advanced cancers.Invest New Drugs · 202127 citationsRCR 1.4
- Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC-A Brief Report.J Thorac Oncol · 202524 citationsRCR 4.3
- Updated Overall Survival Analysis From the Phase II PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer.J Clin Oncol · 202515 citationsRCR 2.3
- Phase I Dose-Escalation Trial Combining Olaparib and Thoracic Radiotherapy in Extensive-Stage Small Cell Lung Cancer.Clin Cancer Res · 20251 citationsRCR 0.1